RT Journal Article
SR Electronic
T1 Women’s experiences and acceptability of self-administered, home delivered, intravaginal 5-Fluorouracil cream for cervical precancer treatment in Kenya
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.27.24312651
DO 10.1101/2024.08.27.24312651
A1 Mungo, Chemtai
A1 Adewumi, Konyin
A1 Rop, Mercy
A1 Owaya, Antony
A1 Adoyo, Everlyn
A1 Kachoria, Aparna Ghosh
A1 Tang, Jennifer H
A1 Rahangdale, Lisa
YR 2024
UL http://medrxiv.org/content/early/2024/11/09/2024.08.27.24312651.abstract
AB BACKGROUND Innovative strategies are essential to meet the World Health Organization’s 90/70/90 cervical cancer elimination targets, aiming for 90% access to precancer treatment globally by 2030. In low-and middle-income countries (LMICs) where most cervical cancer cases occur, access to precancer treatment is severely limited. Scalable solutions like self-administered topical therapies can help close this gap. In a recent Phase I trial (ClinicalTrials.gov NCT05362955), we demonstrated safety and adherence to self-administered intravaginal 5% 5-Fluorouracil (5FU) cream as an adjuvant therapy for cervical precancer among women living with HIV (WLWH) in rural Kenya. To understand women’s experiences with self-administered 5FU, we evaluated the acceptability of this intervention among trial participants.METHODS All 12 participants from the Phase I trial completed a structured questionnaire and in-depth semi-structured interviews in their preferred language, focusing on their experiences with 5FU self-administration, challenges faced, and overall acceptability of the intervention, including whether they would use it again or recommend it to someone who needed it. Quantitative data were analyzed using descriptive statistics. In the qualitative study, acceptability was defined as “the perception that a given treatment is agreeable, palatable, or satisfactory.” A thematic analysis was conducted using five dimensions of acceptability: content, complexity, comfort, delivery, and credibility.RESULTS The mean age was 43.9 years (SD 4.4), and 7 (58%) had primary education or less. While some participants reported feelings of uncertainty when they started using 5FU, at the end of the study, all twelve participants strongly agreed that the cream was safe and were confident they used it correctly. Most participants (91.7%) experienced no discomfort with the vaginal applicator, and most reported using tampons overnight after 5FU use, as recommended. Qualitative findings revealed that favorable perceptions of self-administered 5FU were driven by its ease of use, the discrete nature of the treatment, and the comfort of home application. The main challenges included correctly measuring the study drug, finding a private place at home to self-administer, and the need to use condoms during treatment. Compared to their previous ablation or excision treatments, participants found 5FU to be less painful, and all would prefer a self-administered treatment instead of a procedure if it were an option.CONCLUSION Self-administered intravaginal 5FU as an adjuvant treatment for cervical precancer among women living with HIV in Kenya was highly acceptable. Randomized studies of 5FU and other topical therapies in LMICs are needed to evaluate their use in closing the current precancer treatment gaps in these settings.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05362955Funding StatementThis research was supported by the Womens Reproductive Health Research Career Development Grants (5-K12-HD103085-04) and the Victorias Secret Global Fund for Womens Cancers Career Development Award, in Partnership with Pelotonia and the American Association of Cancer Research (AACR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review boards at the University of North Carolina at Chapel Hill (21-3265) and the Kenya Medical Research Institute (KEMRI/SERU/CMR/4555). All participants provided informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized research data are available upon reasonable request.